Oruka Therapeutics (NASDAQ:ORKA) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Oruka Therapeutics (NASDAQ:ORKA) from a hold rating to a sell rating in a research note issued to investors on Sunday morning.

Several other brokerages also recently weighed in on ORKA. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Wedbush restated an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. BTIG Research reaffirmed a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Finally, UBS Group increased their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Price Performance

ORKA stock opened at $113.08 on Friday. The company has a market cap of $7.49 billion, a price-to-earnings ratio of -55.70 and a beta of -0.34. The company has a fifty day moving average price of $89.42 and a 200 day moving average price of $63.91. Oruka Therapeutics has a 12 month low of $14.08 and a 12 month high of $113.31.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, analysts anticipate that Oruka Therapeutics will post -2.27 earnings per share for the current year.

Insider Activity

In other news, Director Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $58.97, for a total value of $6,191,850.00. Following the sale, the director owned 73,743 shares of the company’s stock, valued at $4,348,624.71. The trade was a 58.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the transaction, the senior vice president owned 15,312 shares in the company, valued at approximately $1,633,177.92. This trade represents a 39.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 188,116 shares of company stock worth $12,828,383 in the last 90 days. Corporate insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ORKA. Orion Capital Management LLC acquired a new position in Oruka Therapeutics during the 2nd quarter worth approximately $91,000. Royal Bank of Canada raised its stake in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at approximately $37,000. PNC Financial Services Group Inc. acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $39,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Oruka Therapeutics in the fourth quarter valued at approximately $67,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.